UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
批准号:
10598362
负责人:
WENDELL A LIM
金额:
$5.93万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-09-24 至 2024-08-31
关键词:
AddressAntigensBioinformaticsCell TherapyCellsCellular immunotherapyDatabasesEngineeringGene Expression ProfilingGoalsHematopoietic NeoplasmsImmuneImmune systemImmunologistImmunotherapeutic agentMalignant NeoplasmsModelingNormal tissue morphologyPattern RecognitionProcessSafetyScientistSolidSolid NeoplasmSynthetic immunologyTechnologyblood treatmentcell behaviorcell transformationcellular engineeringchimeric antigen receptor T cellscombatcomputer frameworkdesignengineered T cellsimmunoengineeringin vivonanonanomaterialsneoplastic cellnext generationprogramsprototypesmall moleculetooltraffickingtumortumor microenvironment
中文摘要
项目摘要/摘要
加州大学旧金山分校合成免疫学中心:重组免疫系统以抗击癌症的工具
免疫系统已经成为抗击癌症的非常强大的工具。其中最
有效的药物是经过改造的T细胞,可以识别和杀死肿瘤细胞。尽管如此,我们有能力
设计T细胞和其他免疫细胞并对它们进行编程以执行新功能仍然是相对原始的。
除了CAR T细胞用于治疗血癌外,大多数基因工程细胞疗法都是有风险的,潜在风险很高
有毒、不可靠,而且往往无效,特别是那些试图针对实体癌的细胞疗法。我们
假设为了实现工程免疫细胞疗法的承诺,我们必须首先转化细胞
将工程设计为系统和可预测的过程;使用可靠的技术平台和
原则。我们的中心将专注于开发一套复杂的免疫工程平台,以解决
下一代细胞疗法的三个主要需求:
1)癌症的智能识别-开发抗原模式识别电路,引导免疫细胞
最佳识别实体肿瘤并区分正常组织交叉反应,由
基因表达模式的计算生物信息学分析。
2)克服肿瘤微环境-发展多种类型的细胞电路,可以克服
或局部重塑免疫抑制的肿瘤微环境,以促进高效治疗
免疫细胞的运输、增殖、持续与肿瘤杀伤活性
3)用户控制和安全-为了加强对这些功能强大的工程电池的控制和安全性,我们将
开发一套在体内与工程免疫细胞交流和控制其活性的方法,
包括纳米/微米粒子和小分子。
为了实现这些目标,我们组建了加州大学旧金山分校合成免疫学中心,一个紧密整合的
由合成生物学家、免疫学家、生物信息学家、控制学家组成的跨学科团队
工程师和材料科学家。该中心的产品将包括公开提供的零部件工具包
和用于细胞工程的电路,用于快速电路组装的高通量平台,新的可编程
用于控制免疫细胞行为的纳米材料,用于优化肿瘤的可搜索生物信息数据库
用于电路设计和体内电路功能建模/原型的计算框架。
这些平台将有助于推动免疫细胞工程变得更加可靠、可预测、有效和
安然无恙。
英文摘要
Project Summary/Abstract
UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
The immune system has emerged as an extraordinarily powerful tool for combating cancer. One of the most
potent agents are engineered T cells programmed to recognize and kill tumor cells. Nonetheless, our ability to
engineer T cells and other immune cells and program them to execute new functions remains relatively primitive.
Aside from CAR T cells for treatment of blood cancers, most engineered cell therapies are risky, potentially highly
toxic, unreliable and often ineffective, especially those cell therapies that attempt to target solid cancers. We
hypothesize that to fulfil the promise of engineered immune cell therapies, we must first transform cell
engineering into a systematic and predictable process; one that uses reliable technology platforms and
principles. Our center will focus on developing a set of sophisticated immune engineering platforms that address
three major needs in next-generation cell therapies:
1) Smart recognition of cancer – develop antigen-pattern recognition circuits that direct immune cells to
optimally recognize solid tumors and discriminate against normal tissue crossreaction, guided by
computational bioinformatic analysis of gene expression patterns.
2) Overcoming the tumor microenvironment – develop multiple classes of cellular circuits that can overcome
or locally remodel immune-suppressive tumor microenvironments to promote highly efficient therapeutic
immune cell trafficking, proliferation, persistence, and tumor-killing activity
3) User-control and safety – to increase control over and safety of these powerful engineered cells, we will
develop a suite of ways to communicate with and control the activity of engineered immune cells in vivo,
including nano/microparticles and small molecules.
To achieve these goals, we have assembled the UCSF Center for Synthetic Immunology, a tightly integrated
interdisciplinary team that encompasses synthetic biologists, immunologists, bio-informaticists, control
engineers, and materials scientists. The products of this center will include publicly available toolkits of parts
and circuits for cell engineering, high-throughput platforms for rapid circuit assembly, new programmable
nanomaterials for controlling immune cell behavior, searchable bioinformatic databases for optimization of tumor
recognition, and computational frameworks for circuit design and for modeling/prototyping in vivo circuit function.
These platforms will help to advance immune cell engineering to be far more reliable, predictable, effective and
safe.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Engineering synthetic immune cells with modular sentinel and therapeutic functions for T1D
-
批准号:10594512
-
项目类别:
-
资助金额:$83.16万
-
财政年份:2022
-
负责人:WENDELL A LIM
-
依托单位:
Ameliorating off-target toxicities of CAR T cells by engineering NOT gates
-
批准号:10657356
-
项目类别:
-
资助金额:$44.29万
-
财政年份:2022
-
负责人:WENDELL A LIM
-
依托单位:
Engineering synthetic immune cells with modular sentinel and therapeutic functions for T1D
-
批准号:10436126
-
项目类别:
-
资助金额:$83.08万
-
财政年份:2022
-
负责人:WENDELL A LIM
-
依托单位:
Ameliorating off-target toxicities of CAR T cells by engineering NOT gates
-
批准号:10362126
-
项目类别:
-
资助金额:$45.11万
-
财政年份:2022
-
负责人:WENDELL A LIM
-
依托单位:
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells
-
批准号:10094815
-
项目类别:
-
资助金额:$56.32万
-
财政年份:2020
-
负责人:WENDELL A LIM
-
依托单位:
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells
-
批准号:10559489
-
项目类别:
-
资助金额:$55.2万
-
财政年份:2020
-
负责人:WENDELL A LIM
-
依托单位:
Recognizing the tumor ecosystem: Integrating stromal and cancer antigen signals to achieve precision recognition of solid tumors by CAR T cells
-
批准号:10310406
-
项目类别:
-
资助金额:$14.7万
-
财政年份:2020
-
负责人:WENDELL A LIM
-
依托单位:
Engineering synthetic helper cells that autonomously deliver orthogonal IL-2 to selectively promote therapeutic T cell proliferation in tumors
-
批准号:10285941
-
项目类别:
-
资助金额:$25.0万
-
财政年份:2019
-
负责人:WENDELL A LIM
-
依托单位:
UCSF Center for Synthetic Immunology: Tools to Reprogram the Immune System to Combat Cancer
-
批准号:10598367
-
项目类别:
-
资助金额:$5.93万
-
财政年份:2019
-
负责人:WENDELL A LIM
-
依托单位:
Protein Recognition in Signal Transduction
-
批准号:10460232
-
项目类别:
-
资助金额:$33.83万
-
财政年份:2018
-
负责人:WENDELL A LIM
-
依托单位:
Protein Recognition in Signal Transduction
-
批准号:10214557
-
项目类别:
-
资助金额:$34.52万
-
财政年份:2018
-
负责人:WENDELL A LIM
-
依托单位:
Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic Cells
-
批准号:9545542
-
项目类别:
-
资助金额:$66.13万
-
财政年份:2014
-
负责人:WENDELL A LIM
-
依托单位:
Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic Cells
-
批准号:9119791
-
项目类别:
-
资助金额:$66.11万
-
财政年份:2014
-
负责人:WENDELL A LIM
-
依托单位:
Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic Cells
-
批准号:9319242
-
项目类别:
-
资助金额:$66.13万
-
财政年份:2014
-
负责人:WENDELL A LIM
-
依托单位:
Redesigning the T cell: Using Synthetic Biology to Engineer Therapeutic Cells
-
批准号:8753520
-
项目类别:
-
资助金额:$68.03万
-
财政年份:2014
-
负责人:WENDELL A LIM
-
依托单位:
Harnessing CRISPR for Targeted and Inducible Epigenomic Reprogramming
-
批准号:9307796
-
项目类别:
-
资助金额:$51.35万
-
财政年份:2013
-
负责人:WENDELL A LIM
-
依托单位:
Harnessing CRISPR for Targeted and Inducible Epigenomic Reprogramming
-
批准号:8642014
-
项目类别:
-
资助金额:$50.9万
-
财政年份:2013
-
负责人:WENDELL A LIM
-
依托单位:
Harnessing CRISPR for Targeted and Inducible Epigenomic Reprogramming
-
批准号:9073782
-
项目类别:
-
资助金额:$11.98万
-
财政年份:2013
-
负责人:WENDELL A LIM
-
依托单位:
Harnessing CRISPR for Targeted and Inducible Epigenomic Reprogramming
-
批准号:8735919
-
项目类别:
-
资助金额:$51.21万
-
财政年份:2013
-
负责人:WENDELL A LIM
-
依托单位:
ELUCIDATING THE KINETIC MECHANISM OF SCAFFOLD-MEDIATED MAP KINASE SIGNALING
-
批准号:8363800
-
项目类别:
-
资助金额:$0.06万
-
财政年份:2011
-
负责人:WENDELL A LIM
-
依托单位:
国内基金
海外基金
Neo-antigens暴露对肾移植术后体液性排斥反应的影响及其机制研究
-
批准号:2022J011295
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:王亚伟
-
依托单位:
结核分枝杆菌持续感染期抗原(latency antigens)的重组BCG疫苗研究
-
批准号:30801055
-
项目类别:青年科学基金项目
-
资助金额:19.0万元
-
批准年份:2008
-
负责人:王丽梅
-
依托单位: